Urothelial Cancer: DDR Gene Testing for Chemotherapy Response

We are studying whether changes in DDR genes can help predict how well patients with advanced urothelial cancer respond to platinum-based chemotherapy. This may lead to better treatment decisions for patients based on their genetic profile.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Carboplatin
Carboplatin is a chemotherapy medicine used to treat various types of cancer.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Avelumab
Avelumab is a substance that boosts the immune system to help the body recognize and attack certain types of cancer.
Carboplatin
Carboplatin is a chemotherapy substance used to treat various cancers by damaging cancer cells and slowing tumor growth.
Cisplatin
Cisplatin is a substance used in chemotherapy to kill or stop the growth of cancer cells.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Carbo-Cell
Carbomedac
Carboplan

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
University Hospital Consorziale Policlinico
Oncologia Medica
Bari, Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Oncologia
Beinasco, Italy
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Oncologia Medica
Bologna, Italy

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.